Search
Rigel Pharmaceuticals Inc
RIGLAdd to Watchlist
32.910USD
-0.460-1.38%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
602.61MMarket Cap
1.63P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Rigel Pharmaceuticals Inc is 8.00, ranking 55 out of 157 in the Pharmaceuticals industry. The average price target is 42.00, with a high of 69.00 and a low of 24.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
53.200
Target Price
+59.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
65
Total
4
Median
6
Average
Company name
Ratings
Analysts
Rigel Pharmaceuticals Inc
RIGL
5
Apple Inc
AAPL
49
Ge Vernova Inc
GEV
37
Tapestry Inc
TPR
24
Verisk Analytics Inc
VRSK
20
Avantor Inc
AVTR
19
1
2
3
...
13
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Rigel Pharmaceuticals Inc's expected revenue for the next quarter?
Rigel Pharmaceuticals Inc's expected revenue is 68.65M.
What is Rigel Pharmaceuticals Inc's price target?
Analysts forecast that Rigel Pharmaceuticals Inc's price target is USD 42.00, with the highest forecast at USD 69.00 and the lowest forecast at USD 24.00.
How have Rigel Pharmaceuticals IncRIGL's recent earnings per share performed?
The market expectation was USD 0.47, while Rigel Pharmaceuticals IncRIGL's earnings per share (EPS) for the previous quarter was USD 14.72. EPS for the next quarter is expected at USD 0.94.
What is the analyst rating for Rigel Pharmaceuticals Inc?
Based on the ratings of Rigel Pharmaceuticals Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
